A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
NCT ID: NCT02932449
Last Updated: 2025-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1500 participants
OBSERVATIONAL
2016-10-31
2025-01-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05292872
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis
NCT05104853
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124
Pentoxifylline for Primary Biliary Cirrhosis
NCT01249092
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
NCT02247934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Simultaneous enrollment in another prospective registry or clinical trial or study where PBC treatment outcomes are reported, except where approved or conducted as an adjunct project of TARGET-PBC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Target PharmaSolutions, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute for Liver Health
Chandler, Arizona, United States
Banner University Medical Center
Phoenix, Arizona, United States
Mayo Clinic
Phoenix, Arizona, United States
University of Arkansas
Little Rock, Arkansas, United States
Stanford University Medical Center
Palo Alto, California, United States
California Liver Research Institute
Pasadena, California, United States
University of California Davis
Sacramento, California, United States
University of Colorado- Anschutz Medical Campus
Aurora, Colorado, United States
Yale Internal Medicine, Digestive Diseases
New Haven, Connecticut, United States
Gastro Florida
Clearwater, Florida, United States
University of Florida Hepatology Research
Gainesville, Florida, United States
SCFLD/University of Miami
Miami, Florida, United States
Piedmont Atlanta Hospital
Atlanta, Georgia, United States
Illinois Gastroenterology Group
Arlington Heights, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
Mercy Medical Center, GI Research
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Southern Therapy and Advanced Research LLC (STAR)
Jackson, Mississippi, United States
Saint Louis University
St Louis, Missouri, United States
University of Nebraska
Omaha, Nebraska, United States
Sandra Atlas Bass Center for Liver Diseases
Manhasset, New York, United States
NYU Langone Health
New York, New York, United States
Weill Cornell Medical College
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Center for Liver Disease and Transplant at CMC
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Ohio State University Medical Center
Columbus, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Baylor,Scott and White All Saints
Fort Worth, Texas, United States
Liver Associates of Texas, P.A.
Houston, Texas, United States
Pinnacle Clinical Research
Live Oak, Texas, United States
Bon Secours Liver Institute of Virginia
Richmond, Virginia, United States
Virginia Commonwealth University (VCU)
Richmond, Virginia, United States
University of Washington
Seattle, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TARGET-PBC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.